Dendreon In Trouble
AuthorDendreon Corporation (NASDAQ: DNDN) is in trouble. That is what the performance is telling investors. The maker of Provenge as a late-stage prostate cancer treatment has three issues working against it. The company has…
Health and Healthcare
All Health and Healthcare Articles
Newest first · Page 320IPO Filing From KYTHERA: Fighting The Double Chin
KYTHERA Biopharmaceuticals, Inc. has just joined in with the companies which have filed to come public via an initial public offering. The common stock plans to be listed on The NASDAQ Global Market under…
Rosetta Genomics Share Offering: No Good Deeds Go Unpunished
Rosetta Genomics, Ltd. (NASDAQ: ROSG) was an exponential winner on Wednesday due to getting a Medicare reimbursement ruling in its favor. The company had announced that the Medicare Administrative Contractor approved its miRview® mets²…
Rosetta Genomics Joins Exponential Explosion Club on Medicare Coverage
Rosetta Genomics Ltd. (NASDAQ: ROSG) is not often in the news, but it is in the news a big way now. The microRNA-based molecular diagnostic test maker has announced that Novitas, the designated Medicare Administrative…
NASDAQ Changes Up Biotech Index Members & Weightings
Index changes are generally speaking a fairly routine event. They can also create underlying moves in the companies added and deleted from them as money management firms often buy and sell shares, as do…
Can A European Approval of Pixantrone Save Cell Therapeutics? (CTIC)
Cell Therapeutics, Inc. (NASDAQ: CTIC) is about as controversial of a biotech stock as there can be. It often traded huge volume around drug approval or study news, and shares rose after being halted…
Taking An Early Look at 2012 ASCO Biotech/Cancer Stocks (DNDN, LLY, ARIA, ARRY, BVTI, ABPI, CLDX, CYTR, GALE, EXEL, GNBT, GHDX, IMGN, NKTR, NLNK, PCYC, SGEN)
It is now getting close to the middle of May, and that means one thing for biotech investors. The king of biotech and pharma events is about to take place. The 2012 annual meeting…
Biotechs Bucking The Dendreon Trap & Curse (DNDN, VRTX, VVUS, ARNA, ALNY, AMGN, SVNT)
When we issued our earnings previews for the week ahead, it looked as though Dendreon Corporation (NASDAQ: DNDN) had a chance of really setting the trend for the entire biotech sector this week. That…
America Adjusts for Obesity
Authors of a new CDC study, widely covered in the press, reported that the number of Americans considered obese will rise to 42% of the population by 2030. The medical costs of the shift will be…
Dendreon, When 200% Sales Growth Is Not Enough (DNDN)
AuthorDendreon Corporation (NASDAQ: DNDN) has reported its quarterly results and the reaction is a bit cool. This is growth of almost 200%, as net product revenue for the quarter was $82.0 million versus $27.0…
Vertex Sees Billions In Value on Cystic Fibrosis Results (VRTX)
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) is trading up so much higher that you might think the company is being acquired. The real reason for the huge share gains is based upon results of a…
Herbalife Sinks on Lack of Info (HLF, NUS)
Shares of Herbalife Ltd. (NYSE: HLF) are trading at about 9x average daily volume today following some weak answers on the company’s conference call yesterday. The network marketer of nutrition and weight loss products…
Another Medical Company Goes To Europe… Kensey Nash Buyout At All-Time High (KNSY)
Kensey Nash Corporation (NASDAQ: KNSY) is well-known for its regenerative tissue materials, but it is soon going to be known under a new name or at least with a new owner rather than Joe Public…
Second Look: Is There Any Real Value Left In Savient? (SVNT, DNDN, SVNT)
Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) already had problems before a fund called Tang Capital accused it of being insolvent this week. Over the last year this stock has fallen down steadily just like its…
Fast-Acting Erectile Dysfunction Drug Penetrates The Market
Men with erectile dysfunction can get relief twice as quickly as was possible in the past. VIVUS, Inc. (NASDAQ: VVUS) received FDA approval for STENDRA (avanafil) tablets. The firm says that it is the “first…